Every 10-Q that Aprea Therapeutics, Inc. (APRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. is a clinical-stage oncology company developing targeted, synthetic lethality-based therapies. For the quarter ended June 30, 2026, it reported a net loss of $3.6 million (basic and diluted $0.07 per share) with no grant revenue, compared with a $3.2 million loss a year earlier. Research and development expenses rose to $2.5 million, driven mainly by its lead WEE1 inhibitor APR-1051, while general and administrative costs were steady at about $1.6 million.
Cash, cash equivalents and restricted cash increased sharply to $41.3 million at June 30, 2026 from $14.6 million at year-end 2025, primarily due to three late-2025 and early-2026 private placements and warrant financings totaling roughly $38.7 million in upfront gross proceeds. The company states this cash should fund operations into the first quarter of 2028.
Clinically, APR-1051 showed early activity in the Phase 1 ACESOT-1051 study, including two partial responses in PPP2R1A-mutated endometrial cancer and multiple patients with stable disease. Enrollment is expanding, with a larger cohort planned in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. ATR inhibitor ATRN-119 completed dose escalation in the ABOYA-119 study; development is now focused on potential combination regimens. A macrocyclic DYRK1A/B inhibitor remains in preclinical development with possible IND-enabling entry in late 2026, subject to resources.
Aprea Therapeutics, Inc. reported a Q1 2026 net loss of $3.3 million, slightly improved from $3.9 million a year earlier, as lower research and development spending offset the end of grant revenue. Cash and cash equivalents reached $46.5 million, and management believes this will fund operations into the first quarter of 2028.
Research and development expenses fell to $1.6 million, mainly from reduced ATRN-119 monotherapy activity, while general and administrative costs were stable at about $1.8 million. Operating cash outflow was $2.8 million in the quarter.
The company strengthened its balance sheet with approximately $34.6 million in net proceeds from January and March 2026 private placements involving common stock and pre-funded warrants. Aprea continues to advance its synthetic lethality oncology pipeline, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, supported by an expanded base of warrants and equity capital.
Aprea Therapeutics (APRE) filed its Q3 2025 10‑Q, reporting a net loss of $2,972,410 and cash and cash equivalents of $13,718,052. Operating expenses declined to $3,119,236 from $4,451,637 a year ago as both R&D and G&A trended lower. Interest income was $150,669.
The company stated that its September 30, 2025 cash balance will not fund operations for at least twelve months from issuance of the financial statements, indicating substantial doubt about continuing as a going concern. To bolster liquidity, Aprea raised approximately $0.8 million net during the nine months via its at‑the‑market program, issuing 468,567 shares. For the nine months, net loss was $10,143,939.
Program updates included setting the recommended Phase 2 dose of ATRN‑119 at 1,100 mg once daily and a strategic pause in further monotherapy enrollment while exploring combination studies. Common shares outstanding were 6,310,673 as of November 11, 2025.
Aprea Therapeutics reported cash and cash equivalents of $16.5 million and total assets of $17.3 million, with an accumulated deficit of $328.2 million. The company recorded a net loss of $7.17 million for the six months and used $6.8 million of cash in operating activities over the same period. Grant revenue declined to $0.28 million year-to-date, largely from reduced NIH funding. Research and development spending was $4.40 million for six months, driven by ATRN-119 and APR-1051 programs, and the company expects safety/efficacy data in the second half of the year with RP2D decisions expected in the first half of 2026. Management states existing cash is not sufficient to fund operations for at least twelve months and has concluded substantial doubt exists about its ability to continue as a going concern, and is seeking additional funding.